Autophagy as an essential cellular antioxidant pathway in neurodegenerative disease

Dorsey, 2013, The coming crisis: obtaining care for the growing burden of neurodegenerative conditions, Neurology, 80, 1989, 10.1212/WNL.0b013e318293e2ce Lee, 2012, Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling, Biochem. J., 441, 523, 10.1042/BJ20111451 Hohn, 2013, Lipofuscin: formation, effects and role of macroautophagy, Redox Biol., 1, 140, 10.1016/j.redox.2013.01.006 Zhang, 2013, Autophagy and mitophagy in cellular damage control, Redox Biol., 1, 19, 10.1016/j.redox.2012.11.008 Kalyanaraman, 2013, Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms, Redox Biol., 1, 244, 10.1016/j.redox.2013.01.014 Beckman, 2009, Understanding peroxynitrite biochemistry and its potential for treating human diseases, Arch. Biochem. Biophys., 484, 114, 10.1016/j.abb.2009.03.013 Pacher, 2007, Nitric oxide and peroxynitrite in health and disease, Physiol. Rev., 87, 315, 10.1152/physrev.00029.2006 Szabo, 2007, Peroxynitrite: biochemistry, pathophysiology and development of therapeutics, Nat. Rev. Drug Discov., 6, 662, 10.1038/nrd2222 Tieu, 2003, Nitric oxide and reactive oxygen species in Parkinson′s disease, IUBMB Life, 55, 329, 10.1080/1521654032000114320 Brown, 2010, Inflammatory neurodegeneration and mechanisms of microglial killing of neurons, Mol. Neurobiol., 41, 242, 10.1007/s12035-010-8105-9 Brown, 2010, Nitric oxide and neuronal death, Nitric. Oxide, 23, 153, 10.1016/j.niox.2010.06.001 Butterfield, 2011, Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer′s disease, Free Radic. Res., 45, 59, 10.3109/10715762.2010.520014 Dexter, 1989, Basal lipid peroxidation in substantia nigra is increased in Parkinson′s disease, J. Neurochem., 52, 381, 10.1111/j.1471-4159.1989.tb09133.x Higdon, 2012, Cell signalling by reactive lipid species: new concepts and molecular mechanisms, Biochem. J., 442, 453, 10.1042/BJ20111752 Yoritaka, 1996, Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, Proc. Natl. Acad. Sci. U. S. A., 93, 2696, 10.1073/pnas.93.7.2696 Butterfield, 2002, Lipid peroxidation and protein oxidation in Alzheimer′s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress, Free Radic. Biol. Med., 32, 1050, 10.1016/S0891-5849(02)00794-3 Alam, 1997, A generalised increase in protein carbonyls in the brain in Parkinson′s but not incidental Lewy body disease, J. Neurochem., 69, 1326, 10.1046/j.1471-4159.1997.69031326.x Keeney, 2006, Parkinson′s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled, J. Neurosci., 26, 5256, 10.1523/JNEUROSCI.0984-06.2006 Choi, 2004, Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson′s and Alzheimer′s diseases, J. Biol. Chem., 279, 13256, 10.1074/jbc.M314124200 Choi, 2006, Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases, J. Biol. Chem., 281, 10816, 10.1074/jbc.M509079200 Duda, 2000, Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies, Am. J. Pathol., 157, 1439, 10.1016/S0002-9440(10)64781-5 Darley-Usmar, 1992, The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein, Free Radic. Res. Commun., 17, 9, 10.3109/10715769209061085 Mecocci, 1993, Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain, Ann. Neurol., 34, 609, 10.1002/ana.410340416 Alam, 1997, Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra, J. Neurochem., 69, 1196, 10.1046/j.1471-4159.1997.69031196.x Zhang, 1999, Parkinson′s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons, Am. J. Pathol., 154, 1423, 10.1016/S0002-9440(10)65396-5 Wang, 2005, Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer′s disease, J. Neurochem., 93, 953, 10.1111/j.1471-4159.2005.03053.x Halliwell, 2012, Free radicals and antioxidants: updating a personal view, Nutr. Rev., 70, 257, 10.1111/j.1753-4887.2012.00476.x Raps, 1989, Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons, Brain Res., 493, 398, 10.1016/0006-8993(89)91178-5 Slivka, 1987, Histochemical evaluation of glutathione in brain, Brain Res., 409, 275, 10.1016/0006-8993(87)90712-8 Kang, 1999, Brain gamma-glutamyl cysteine synthetase (GCS) mRNA expression patterns correlate with regional-specific enzyme activities and glutathione levels, J. Neurosci. Res., 58, 436, 10.1002/(SICI)1097-4547(19991101)58:3<436::AID-JNR9>3.0.CO;2-B Rebrin, 2003, Effects of age and caloric restriction on glutathione redox state in mice, Free Radic. Biol. Med., 35, 626, 10.1016/S0891-5849(03)00388-5 Pearce, 1997, Alterations in the distribution of glutathione in the substantia nigra in Parkinson′s disease, J. Neural Transm., 104, 661, 10.1007/BF01291884 Sian, 1994, Alterations in glutathione levels in Parkinson′s disease and other neurodegenerative disorders affecting basal ganglia, Ann. Neurol., 36, 348, 10.1002/ana.410360305 Venkateshappa, 2012, Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson′s disease, Neurochem. Res., 37, 358, 10.1007/s11064-011-0619-7 Harish, 2013, Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson′s disease brains, Neurochem. Res., 38, 186, 10.1007/s11064-012-0907-x Mythri, 2011, Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson′s disease brains, Neurochem. Res., 36, 1452, 10.1007/s11064-011-0471-9 Krapfenbauer, 2003, Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders, Brain Res., 967, 152, 10.1016/S0006-8993(02)04243-9 Werner, 2008, Proteome analysis of human substantia nigra in Parkinson′s disease, Proteome. Sci., 6, 8, 10.1186/1477-5956-6-8 Paraskevas, 2003, Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism, J. Neurol. Sci., 215, 51, 10.1016/S0022-510X(03)00184-9 Gotz, 2000, Altered redox state of platelet coenzyme Q10 in Parkinson′s disease, J. Neural Transm., 107, 41, 10.1007/s007020050003 Spencer, 1998, Conjugates of catecholamines with cysteine and GSH in Parkinson′s disease: possible mechanisms of formation involving reactive oxygen species, J. Neurochem., 71, 2112, 10.1046/j.1471-4159.1998.71052112.x Trinh, 2013, Advances in the genetics of Parkinson disease, Nat. Rev. Neurol., 10.1038/nrneurol.2013.132 Corti, 2011, What genetics tells us about the causes and mechanisms of Parkinson′s disease, Physiol Rev., 91, 1161, 10.1152/physrev.00022.2010 Byers, 2011, SNCA triplication Parkinson′s patient′s iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress, PLoS ONE, 6, e26159, 10.1371/journal.pone.0026159 Su, 2013, Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation, Hum. Mol. Genet., 22, 4545, 10.1093/hmg/ddt301 Abramov, 2011, Bioenergetic consequences of PINK1 mutations in Parkinson disease, PLoS ONE, 6, e25622, 10.1371/journal.pone.0025622 Sanders, 2013, LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson′s disease patients: reversal by gene correction, Neurobiol. Dis., 62C, 381 Imaizumi, 2012, Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue, Mol. Brain, 5, 35, 10.1186/1756-6606-5-35 Dauer, 2003, Parkinson′s disease: mechanisms and models, Neuron, 39, 889, 10.1016/S0896-6273(03)00568-3 Dranka, 2012, Alterations in bioenergetic function induced by Parkinson′s disease mimetic compounds: lack of correlation with superoxide generation, J. Neurochem., 10.1111/j.1471-4159.2012.07836.x Giordano, 2012, Distinct Effects of Rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on Cellular Bioenergetics and Cell Death, PLoS ONE, 7, e44610, 10.1371/journal.pone.0044610 Mandavilli, 2000, DNA damage in brain mitochondria caused by aging and MPTP treatment, Brain Res., 885, 45, 10.1016/S0006-8993(00)02926-7 Cassarino, 1997, Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson′s disease, Biochim. Biophys. Acta, 1362, 77, 10.1016/S0925-4439(97)00070-7 Tanner, 2011, Rotenone, paraquat, and Parkinson′s disease, Environ. Health Perspect., 119, 866, 10.1289/ehp.1002839 Marella, 2008, Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson′s disease, PLoS ONE, 3, e1433, 10.1371/journal.pone.0001433 Bashkatova, 2004, Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain, Exp. Neurol., 186, 235, 10.1016/j.expneurol.2003.12.005 Mastroberardino, 2009, A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson′s disease, Neurobiol. Dis., 34, 417, 10.1016/j.nbd.2009.02.009 Horowitz, 2011, Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults, Antioxid. Redox Signal, 15, 855, 10.1089/ars.2010.3629 Sherer, 2003, Mechanism of toxicity in rotenone models of Parkinson′s disease, J. Neurosci., 23, 10756, 10.1523/JNEUROSCI.23-34-10756.2003 Murphy, 2009, How mitochondria produce reactive oxygen species, Biochem. J., 417, 1, 10.1042/BJ20081386 Fussell, 2011, Redox cycling and increased oxygen utilization contribute to diquat-induced oxidative stress and cytotoxicity in Chinese hamster ovary cells overexpressing NADPH-cytochrome P450 reductase, Free Radic. Biol. Med., 50, 874, 10.1016/j.freeradbiomed.2010.12.035 Richardson, 2005, Paraquat neurotoxicity is distinct from that of MPTP and rotenone, Toxicol. Sci., 88, 193, 10.1093/toxsci/kfi304 Cannon, 2010, Neurotoxic in vivo models of Parkinson′s disease recent advances, Prog. Brain Res., 184, 17, 10.1016/S0079-6123(10)84002-6 Liang, 2013, Glutathione deficiency in Gclm null mice results in complex I inhibition and dopamine depletion following paraquat administration, Toxicol. Sci., 134, 366, 10.1093/toxsci/kft112 Andrew, 1993, The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls, Neurochem. Res., 18, 1175, 10.1007/BF00978370 Kikuchi, 2011, Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson′s disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion, J. Cell Physiol., 226, 1390, 10.1002/jcp.22467 Kumar, 1995, Free radical-generated neurotoxicity of 6-hydroxydopamine, J. Neurochem., 64, 1703, 10.1046/j.1471-4159.1995.64041703.x Khan, 2010, Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson′s disease, Brain Res., 1328, 139, 10.1016/j.brainres.2010.02.031 Perry, 1985, Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse, Neurosci. Lett., 60, 109, 10.1016/0304-3940(85)90229-0 Cohen, 1984, Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys, Eur. J. Pharmacol., 106, 209, 10.1016/0014-2999(84)90700-3 Matthews, 1999, Creatine and cyclocreatine attenuate MPTP neurotoxicity, Exp. Neurol., 157, 142, 10.1006/exnr.1999.7049 Moussaoui, 2000, The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson′s disease, Exp. Neurol., 166, 235, 10.1006/exnr.2000.7516 Horvath, 2003, Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson′s disease, Endocrinology, 144, 2757, 10.1210/en.2003-0163 Levites, 2001, Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration, J. Neurochem., 78, 1073, 10.1046/j.1471-4159.2001.00490.x Karunakaran, 2007, Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson′s disease: protection by alpha-lipoic acid, FASEB J., 21, 2226, 10.1096/fj.06-7580com Lawler, 2002, Direct antioxidant properties of creatine, Biochem. Biophys. Res. Commun., 290, 47, 10.1006/bbrc.2001.6164 Bahat-Stroomza, 2005, A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson′s disease, Eur. J. Neurosci., 21, 637, 10.1111/j.1460-9568.2005.03889.x Kawasaki, 2007, Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum, J. Pharmacol. Exp. Ther., 322, 274, 10.1124/jpet.106.119206 Xiong, 2011, Edaravone guards dopamine neurons in a rotenone model for Parkinson′s disease, PLoS ONE, 6, e20677, 10.1371/journal.pone.0020677 Yuan, 2008, Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons, BMC Neurosci., 9, 75, 10.1186/1471-2202-9-75 Clark, 2010, Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice, PLoS ONE, 5, e12333, 10.1371/journal.pone.0012333 1989. DATATOP: a multicenter controlled clinical trial in early Parkinson′s disease. Parkinson Study Group. Arch. Neurol. 46:1052–1060. Shoulson, 1989, Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group, Acta Neurol. Scand., Suppl 126, 171, 10.1111/j.1600-0404.1989.tb01798.x 2002. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol. 59:1937–1943. Rascol, 2011, A double-blind, delayed-start trial of rasagiline in Parkinson′s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes, Lancet Neurol., 10, 415, 10.1016/S1474-4422(11)70073-4 Olanow, 2008, A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson′s disease (the ADAGIO study): rationale, design, and baseline characteristics, Mov Disord., 23, 2194, 10.1002/mds.22218 Bender, 2006, Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial, Neurology, 67, 1262, 10.1212/01.wnl.0000238518.34389.12 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671. Elm, 2012, Design innovations and baseline findings in a long-term Parkinson′s trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson′s Disease Long-Term Study-1, Mov. Disord., 27, 1513, 10.1002/mds.25175 Shults, 2002, Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline, Arch. Neurol., 59, 1541, 10.1001/archneur.59.10.1541 2007. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20–28. Murphy, 2007, Targeting antioxidants to mitochondria by conjugation to lipophilic cations, Annu. Rev. Pharmacol. Toxicol., 47, 629, 10.1146/annurev.pharmtox.47.120505.105110 Snow, 2010, A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson′s disease, Mov. Disord., 25, 1670, 10.1002/mds.23148 Jin, 2013, Mitochondria-targeted antioxidants for treatment of Parkinson′s disease: preclinical and clinical outcomes, Biochim. Biophys. Acta Kansanen, 2013, The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer, Redox Biol., 1, 45, 10.1016/j.redox.2012.10.001 Levonen, 2004, Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products, Biochem. J., 378, 373, 10.1042/bj20031049 Sauer, 2001, Reactive oxygen species as intracellular messengers during cell growth and differentiation, Cell Physiol. Biochem., 11, 173, 10.1159/000047804 Yin, 2012, Dual role of selected antioxidants found in dietary supplements: crossover between anti- and pro-oxidant activities in the presence of copper, J. Agric. Food Chem., 60, 2554, 10.1021/jf204724w Dodson, 2013, Cellular metabolic and autophagic pathways: traffic control by redox signaling, Free Radic. Biol. Med., 63, 207, 10.1016/j.freeradbiomed.2013.05.014 Hara, 2006, Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice, Nature, 441, 885, 10.1038/nature04724 Komatsu, 2006, Loss of autophagy in the central nervous system causes neurodegeneration in mice, Nature, 441, 880, 10.1038/nature04723 Mortiboys, 2008, Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts, Ann. Neurol., 64, 555, 10.1002/ana.21492 Wang, 2011, PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons, Biochim. Biophys. Acta, 1812, 674, 10.1016/j.bbadis.2011.03.007 Irrcher, 2010, Loss of the Parkinson′s disease-linked gene DJ-1 perturbs mitochondrial dynamics, Hum. Mol. Genet., 19, 3734, 10.1093/hmg/ddq288 Palacino, 2004, Mitochondrial dysfunction and oxidative damage in parkin-deficient mice, J. Biol. Chem., 279, 18614, 10.1074/jbc.M401135200 Gandhi, 2009, PINK1-associated Parkinson′s disease is caused by neuronal vulnerability to calcium-induced cell death, Mol. Cell, 33, 627, 10.1016/j.molcel.2009.02.013 Andres-Mateos, 2007, DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase, Proc. Natl. Acad. Sci. U. S. A., 104, 14807, 10.1073/pnas.0703219104 Guzman, 2010, Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1, Nature, 468, 696, 10.1038/nature09536 Frank-Cannon, 2008, Parkin deficiency increases vulnerability to inflammation-related nigral degeneration, J. Neurosci., 28, 10825, 10.1523/JNEUROSCI.3001-08.2008 Kim, 2005, Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress, Proc. Natl. Acad. Sci. U. S. A, 102, 5215, 10.1073/pnas.0501282102 Manning-Bog, 2007, Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter, Neurobiol. Dis., 27, 141, 10.1016/j.nbd.2007.03.014 Pan, 2009, Rapamycin protects against rotenone-induced apoptosis through autophagy induction, Neuroscience, 164, 541, 10.1016/j.neuroscience.2009.08.014 Xiong, 2011, Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y, Neuroscience, 199, 292, 10.1016/j.neuroscience.2011.10.031 Sarkar, 2007, Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein, J. Biol. Chem., 282, 5641, 10.1074/jbc.M609532200 Fujita, 2011, Nrf2-mediated induction of p62 controls Toll-like receptor-4-driven aggresome-like induced structure formation and autophagic degradation, Proc. Natl. Acad. Sci. U. S. A., 108, 1427, 10.1073/pnas.1014156108 Wu, 2011, Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson′s disease, Neurosignals, 19, 163, 10.1159/000328516 Zhang, 2008, Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia, J. Biol. Chem., 283, 10892, 10.1074/jbc.M800102200 Mahler, 2013, Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?, EPMA J., 4, 5, 10.1186/1878-5085-4-5 Jiang, 2013, Curcumin ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson′s disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy, J. Neuroimmune. Pharmacol., 8, 356, 10.1007/s11481-012-9431-7 Rodriguez-Navarro, 2010, Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation, Neurobiol. Dis., 39, 423, 10.1016/j.nbd.2010.05.014 Castillo, 2013, Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons, Autophagy, 9, 1308, 10.4161/auto.25188 Du, 2013, Trehalose rescues Alzheimer′s disease phenotypes in APP/PS1 transgenic mice, J. Pharm. Pharmacol., 65, 1753, 10.1111/jphp.12108 Ozcelik, 2013, Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice, PLoS ONE, 8, e62459, 10.1371/journal.pone.0062459 Malagelada, 2010, Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson′s disease, J. Neurosci., 30, 1166, 10.1523/JNEUROSCI.3944-09.2010 Tanaka, 2004, Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease, Nat. Med., 10, 148, 10.1038/nm985 Spencer, 2009, Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson′s and Lewy body diseases, J. Neurosci., 29, 13578, 10.1523/JNEUROSCI.4390-09.2009 Decressac, 2013, TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity, Proc. Natl. Acad. Sci. U. S. A., 110, E1817, 10.1073/pnas.1305623110 Bian, 2012, Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice, PLoS ONE, 7, e39953, 10.1371/journal.pone.0039953 Thomas, 2011, DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy, Hum. Mol. Genet., 20, 40, 10.1093/hmg/ddq430 Taira, 2004, DJ-1 has a role in antioxidative stress to prevent cell death, EMBO Rep., 5, 213, 10.1038/sj.embor.7400074 Miyazaki, 2008, DJ-1-binding compounds prevent oxidative stress-induced cell death and movement defect in Parkinson′s disease model rats, J. Neurochem., 105, 2418, 10.1111/j.1471-4159.2008.05327.x Kitamura, 2011, Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson′s disease and stroke model rats, Mol. Neurodegener., 6, 48, 10.1186/1750-1326-6-48 Jeong, 2012, Transduced Tat-DJ-1 protein protects against oxidative stress-induced SH-SY5Y cell death and Parkinson disease in a mouse model, Mol. Cells, 33, 471, 10.1007/s10059-012-2255-8